drug
PREGABALIN
Marketedupdated 6mo agoby RK Pharma Inc
Approvedannual revenue · 2024–2024peak $383M
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval58 co-mentions · 29 sources
- drugpregabalin ER29 co-mentions · 29 sources
- drugLyrica29 co-mentions · 29 sources
- drugpregabalin CR29 co-mentions · 29 sources
- tagSmall Molecule29 co-mentions · 29 sources
- drugpregabalin SR29 co-mentions · 29 sources
- companyLupin Ltd3 co-mentions · 3 sources
- companyStrides Pharma Inc3 co-mentions · 3 sources
all catalysts(14)
approval · 14
Apr 13, 2021
approval
PREGABALIN — FDA approval
PREGABALIN
→
Apr 13, 2021
approval
PREGABALIN — FDA approval
PREGABALIN
→
Mar 8, 2022
approval
PREGABALIN — FDA approval
PREGABALIN
→
May 3, 2022
approval
PREGABALIN — FDA approval
PREGABALIN
→
Apr 26, 2023
approval
PREGABALIN — FDA approval
PREGABALIN
→
Jul 21, 2023
approval
PREGABALIN — FDA approval
PREGABALIN
→
May 30, 2024
approval
PREGABALIN — FDA approval
PREGABALIN
→
Dec 9, 2024
approval
PREGABALIN — FDA approval
PREGABALIN
→
Sep 30, 2025
approval
PREGABALIN — FDA approval
PREGABALIN
→
Feb 2, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Feb 3, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Feb 23, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Feb 23, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Mar 30, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Trials studying PREGABALIN
- phase1Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
- phase2Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
- phase1A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain
- phase2Y-4 to Treat the Postherpetic Neuralgia
- phase3Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
- —A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- phase2Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
- EP1Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 2, 2027
163 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- May 2, 2027patentUS 10022447*PED163d
- May 2, 2027patentUS 10022447*PED163d
- May 2, 2027patentUS 10022447*PED163d
- May 2, 2027patentUS 8945620*PED163d
- May 2, 2027patentUS 8945620*PED163d
- May 2, 2027patentUS 8945620*PED163d
- May 2, 2027patentUS 9144559*PED163d
- May 2, 2027patentUS 9144559*PED163d
- May 2, 2027patentUS 9144559*PED163d
- Nov 2, 2026method-of-use (U-2136)US 10022447
- Nov 2, 2026method-of-use (U-2136)US 10022447
- Nov 2, 2026method-of-use (U-2136)US 10022447
- Nov 2, 2026formulationUS 8945620
- Nov 2, 2026formulationUS 8945620
- Nov 2, 2026formulationUS 8945620
- Nov 2, 2026formulationUS 9144559
- Nov 2, 2026formulationUS 9144559
- Nov 2, 2026formulationUS 9144559
News(1)
- Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in miceWhile psychedelic drugs may be capturing all the attention when it comes to finding fresh ways to treat neuropathic pain, research with mice has suggested a peptide approach may also be effective.fiercebiotech · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that